Navigation Links
Frost & Sullivan Lauds SnooZeal's Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market
Date:2/22/2017

LONDON, Feb. 22, 2017 /PRNewswire/ -- Based on its recent analysis of the sleep apnea therapy market, Frost & Sullivan recognizes SnooZeal, Inc. with the 2017 European New Product Innovation Award. SnooZeal is a highly innovative product that intelligently addresses the root causes of sleep apnea by training the tongue muscles through the clinically proven continuous transmucosal electrical stimulation therapy. Because of its over-the-counter (OTC) status, SnooZeal is one of the most accessible anti-snoring products available in the market today. This ease of access has enabled the company to build a clear competitive advantage in terms of early market access.

Unlike competitive anti-snoring therapies widely prescribed as viable treatment options for sleep apnea patients, SnooZeal's product is based on the simple principle of electrically stimulating the tongue muscles in a non-invasive manner to exercise the over-relaxed muscles. SnooZeal is the only product in the European market used as a therapy during waking hours, enhancing patient convenience and adherence. To be cured of various stages of sleep apnea, the user needs to wear the mouthpiece for at least 20 minutes twice a day for a minimum of 6 weeks.

Continue Reading
SnooZeal Receives 2017 European Sleep Apnea Therapies New Product Innovation Award
SnooZeal Receives 2017 European Sleep Apnea Therapies New Product Innovation Award

"The device is designed to accommodate the treatment needs of patients suffering from various degrees of sleep-disordered breathing by optimizing treatment parameters, which are clinically demonstrated to deliver best results and autonomy to patients," said Frost & Sullivan Industry Analyst Arjunvasan Ambigapathy. "SnooZeal anti-snoring therapy helps patients consciously correct their symptoms, which is clinically demonstrated to be more effective than therapies that are administered when the patient is unconscious. SnooZeal is the only therapeutic option aimed at reversing the cause of this condition, a value that is not seen in most widely-prescribed products in the market today."

One of SnooZeal's most innovative features is its simple design comprising three components:

  • a wearable mouthpiece in the form of a glove that fits onto the tongue
  • a rechargeable control unit attached to the mouthpiece through a mini-USB connection
  • a remote control unit and a smartphone app to manage various treatment parameters that are ideal for patients

When designing the mouthpiece, SnooZeal's team worked with various dentists and maxillofacial surgeons to ensure the product is flexible enough to cover and fit various tongue sizes, without restricting its potential for OTC sales across specific geographies. The product's ease of use; enhanced mobile connectivity; and better collaboration with care providers before, during, and after the therapy have made SnooZeal a truly user-friendly, innovative medical device.

Within a year of its inception, SnooZeal received commercial approval from European healthcare authorities to offer its product OTC as a clinically safe and effective alternative to sleep apnea therapy. The product is awaiting approval from the Food and Drug Administration (FDA) and will soon be available in the United States, which had subsequently garnered the attention of leading investors.

"Being CE-approved for sale in the European market, SnooZeal aims to present its products across both retail and online channels in the United Kingdom, Germany, Switzerland, France, and other major European economies in the near future," noted Arjunvasan Ambigapathy. "With plans to expand its market across emerging economies such as Russia, Mexico, India, China, Canada, and Brazil, SnooZeal's net market value could be higher than most medical device companies in this emerging industry sector and most other companies operating within the European market today."

For successfully meeting the core customer requirements of quality, functionality, clinical effectiveness, and reliability, SnooZeal's sleep apnea product richly deserves Frost & Sullivan's honour.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the product's value-added features/benefits and the increased return on investment (ROI) it offers customers, which in turn raise customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About SnooZeal, Inc.

SnooZeal's antisnoring and sleep apnea device scored a CE mark, making it the first commercially available over-the-counter device that targets the underlying cause of snoring.

The SnooZeal device addresses the excessive relaxation and loss of tongue muscle tone during sleep. The device is worn for 20 to 25 minutes twice a day over six weeks. It delivers electric pulses to the back of the tongue to increase muscle tone with the goal of reversing the over-relaxation of the tongue during sleep. The patient uses a smartphone app to control the treatment.
The daytime treatment differentiates SnooZeal from currently available treatments that are used at night.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that could make or break today's market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the Discussion.

Contact:

Chiara Carella
P: +44 (0) 207.343.8314
F: 210.348.1003
E: chiara.carella@frost.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/frost--sullivan-lauds-snoozeals-unique-electrical-stimulation-therapy-for-sleep-apnea-in-the-european-market-300411214.html


'/>"/>
SOURCE Frost & Sullivan
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets
2. Mega Trends Foster Investment, Innovation and Expansion in Latin America, Finds Frost & Sullivan
3. Frost & Sullivan Market Share Leadership Award Highlights Acuo Technologies Accomplishments in Enterprise Imaging Informatics
4. Development of New Technologies Spurs Molecular Diagnostic Test Volumes in Asia-Pacific, Finds Frost & Sullivan
5. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Global In Vitro Diagnostics Markets Outpace Pharma Industry Growth, finds Frost & Sullivan
8. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
9. Frost & Sullivan: mHealth Serves as the Catalyst for Healthcares Evolution
10. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
11. Frost & Sullivan: Expiration of Patents for Leading Drugs to Bolster the Oral Solid Drug Dosage Excipients Market in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The ... consultations to communities in the greater Denver region, is announcing a charity drive ... a very rare kind of epilepsy. , Until a few months ago, Dominik ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen ... services to communities in the greater Birmingham area, is joining the Chris Hammond ... young people in the region. , The Chris Hammond Youth Foundation maintains athletic ...
(Date:7/21/2017)... PHILADELPHIA (PRWEB) , ... July 21, 2017 , ... ... ARTZ Philadelphia and Theater of Witness , was awarded a $300,000 ... growing humanities program which fosters empathy, comfort with ambiguity and the recognition of ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” ... plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... medical students improve their chances of acceptance to a residency in a United ... have earned degrees outside the U.S. , According to data released by the ...
Breaking Medicine News(10 mins):